SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Thursday, November 1, 2007 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the third quarter 2007.
Individual and institutional investors can access the call via (888) 297-0358 (U.S. and Canada) or (719) 325-2215 (international). To access the live audio webcast or the subsequent archived recording, visit the “Investors and Media -- Calendar of Events” section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis’ website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
CONTACT: Eric Bjerkholt, SVP, Corp. Development & Finance of Sunesis
Pharmaceuticals, Inc., +1-650-266-3717; or Karen L. Bergman,
+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both for Sunesis
Pharmaceuticals, Inc.
Web site: http://www.sunesis.com/
